

5 Safe Stocks In A Dangerous Market

Back in the peak bull days of 2013, it seemed like you could buy just about anything and its price would increase. It's safe to say those days are gone as the market has rediscovered volatility. The S&P 500 is down nearly 3% so far this year and was down 9% just a few weeks ago. More than ever, investors that want to make money in the stock market need to do their due diligence and find companies with strong <u>economic profits</u> and <u>cheap</u> valuations.

Our past 48 long calls have outperformed the market by an average of 4 percentage points, increasing about 1% compared to a 3% loss for the S&P 500. Five of our long calls over the past year stand out for their impressive returns and continued stability. Investors should take another look at these five stocks that are up 10% or more since our original calls and still earn an Attractive-or-better rating.

Universal Insurance Holdings (UVE: \$34/share)

We love companies that consistently earn a strong return on invested capital (<u>ROIC</u>) and UVE has an impressive record here. Its current ROIC of 43% ranks highest of the 45 property and casualty insurers we cover, and since 2007 it's only earned an ROIC below 20% once, in 2007. This long-term track record of efficiency led us to recommend UVE to investors in mid-July.

Since then, the stock has risen by 27% on the back of strong earnings and a \$10 million buyback announcement. Over this same time, the market has dropped nearly 6%. Nothing has changed about the quality of the company and best of all the valuation remains appealing.

UVE has a price to economic book value (PEBV) of just 1.2, which implies that the market expects the company to grow after-tax operating profit (NOPAT) by no more than 20% for the remainder of its corporate life. Given the fact that UVE has more than doubled its NOPAT in just the past two years, we believe it can continue to exceed market expectations.

Foot Locker (FL: \$70/share)

Foot Locker has ridden the consumer recovery to big time profit growth and outperformance for investors since the recession. Its ROIC has improved from 3% in 2008 to 11% so far this year, and over the past five years the stock is up 387% compared to 70% for the S&P 500.

<u>In May</u>, we argued that FL's strong underlying fundamentals and reasonable valuation meant that its streak of outperformance should continue. Sure enough, the stock is up 10% even as the market has dropped by 6% since our initial report. Steady growth in revenues and margin expansion has helped the stock keep rising.

At its current price of \$70/share, FL has a PEBV of 2.1. This ratio implies that the market expects the company to grow profits by no more than 20% over the remainder of its corporate life. However, since 2009, FL has grown NOPAT by 20% compounded annually. If Foot Locker can grow NOPAT by 10% compounded annually for the next decade, the stock is worth \$99/share today – a 41% upside. Such strong business operations coupled with low expectations make Foot Locker an opportunity worth looking into.

Inteliquent (IQNT: \$20/share)

The market keeps looking for reasons to doubt IQNT. When the company reported full year earnings for 2014 in February, the market responded by sending shares tumbling 14%. This response came despite the fact that the company beat on earnings and revenue and earned an ROIC of 28%, its highest since 2009.

We responded to the drop in the share price by <u>urging investors to buy IQNT</u> in early April. Since then, the stock has risen 23% while the market has dropped by 4%. IQNT received a big boost in August after landing a big contract with T-Mobile, which adds the wireless carrier to its list of major customers along with Verizon and AT&T.



Even with this great news, IQNT still has a PEBV of just 1.2. With the new T-Mobile deal providing a big boost to revenue, its margins continuing to expand, and plenty of cash on hand with which to invest in growth, we think IQNT can do much better than the market seems to expect.

Goodyear Tire (GT: \$32/share)

Investors in GT need to look beyond the top line. Declining revenues kept the share price low early this year, but that is in part due to GT's strategy of focusing more on its high value added (HVA) tires, which have higher margins. Even as revenue has fallen in each of the past three years, the company has continued to grow NOPAT and improve ROIC.

With increased efficiency offsetting revenue declines, we <u>made GT our stock pick of the week</u> in February. Since then, the stock is up 18% against a 5% decline in the market. Cheap commodity prices mean improved margins for GT, more people driving, and more needing replacement tires. These trends have manifested in strong profit growth so far this year.

Despite its track record of profit growth, GT trades at a PEBV of 0.7, which implies that the market expects the company's NOPAT to permanently decline by 30%. There's no reason to believe such a drastic decline is going to happen. If Goodyear can grow NOPAT by just 3% compounded annually for the next decade, the stock is worth \$39/share today – a 22% upside from current prices.

Cigna (CI: \$139/share)

Like UVE, CI tops its peer group in terms of ROIC, having earned a 13% return on capital last year. With the strong fundamentals, a cheap valuation, and growth opportunities from the Affordable Care Act and an aging population, we <u>made CI one of our two stocks to own in 2015</u>.

We're not the only one to see value in CI, as competitor Anthem (ANTM) announced a deal to acquire it for \$54 billion in July. The deal consists of ~55% cash and 45% stock and would make the combined company the largest health insurer in the nation. It would be a tie up of two great companies, as ANTM also earns an Attractive rating.

Cl is up 37% since our call, but it still trades at a 21% discount to the acquisition price of \$175. Concerns about the deal failing to pass regulatory muster have weighed on the share price, but investors shouldn't be worried. The upside if the deal goes through is great, but even if it doesn't Cl is still worth the same \$175 share price if it can grow NOPAT by 8% compounded annually for the next 10 years. This scenario seems even more realistic given that over the past five years Cigna has grown NOPAT by 10% compounded annually.

Diligence Matters

Making money in a market like this is tough. It requires lots of effort to <u>dig through the footnotes</u> and discover the true profitability and value of companies. That effort pays off when you find stocks like these that earn great returns in a down market. There's still value to be had in this market, it's just going to take more and more work to find.

Disclosure: David Trainer and Sam McBride receive no compensation to write about any specific stock, sector, style, or theme.



New Constructs[®] – Profile

How New Constructs Creates Value for Clients

- We find it. You benefit. Cutting-edge technology enables us to scale our <u>forensics accounting</u> <u>expertise</u> across 3000+ stocks. We shine a light in the dark corners of SEC filings so our clients can make safer, more informed decisions.
- Our <u>stock rating methodology</u> instantly informs you of the quality of the business and the fairness of the stock's valuation. We do the diligence on earnings quality and valuation so you don't have to.
- In-depth risk/reward analysis underpins our ratings. Our rating methodology grades every stock, ETF, and mutual fund according to what we believe are the 5 most important criteria for assessing the quality of an equity. Each grade reflects the balance of potential risk and reward of buying that equity. Our analysis results in the 5 ratings described below. Very Attractive and Attractive correspond to a "Buy" rating, Very Dangerous and Dangerous correspond to a "Sell" rating, while Neutral corresponds to a "Hold" rating.

QUESTION: Why shouldn't fund research be as good as stock research? Why should fund investors rely on backward-looking price trends? ANSWER: They should not.

Don't judge a fund by its cover. Take a look inside at its holdings and understand the quality of earnings and valuation of the stocks it holds. We enable you to choose the best fund based on its stock-picking merits so you do not have to rely solely on backward-looking technical metrics.

The drivers of our <u>forward-looking fund ratings</u> are Portfolio Management (i.e. the aggregated ratings of its holdings) and Total Annual Costs. The Total Annual Costs Rating (<u>details here</u>) captures the all-in cost of being in a fund over a 3-year holding period, the average period for all fund investors.

Our Philosophy About Research

Accounting data is not designed for equity investors, but for debt investors. <u>Accounting data must be</u> <u>translated into economic earnings</u> to understand the profitability and valuation relevant to equity investors. Respected investors (e.g. Adam Smith, Warren Buffett and Ben Graham) have repeatedly emphasized that accounting results should not be used to value stocks. <u>Economic earnings</u> are what matter because they are:

- 1. Based on the complete set of financial information available.
- 2. Standard for all companies.
- 3. A more accurate representation of the true underlying cash flows of the business.

Additional Information

Incorporated in July 2002, <u>New Constructs</u> is an independent publisher of investment research that provides clients with consulting and research services. We specialize in quality-of-earnings, forensic accounting and discounted cash flow valuation analyses for all U.S. public companies. We translate accounting data from 10Ks into economic financial statements, i.e. <u>NOPAT</u>, <u>Invested Capital</u>, and <u>WACC</u>, to create <u>economic earnings models</u>, which are necessary to understand the true profitability and valuation of companies. Visit the <u>Free Archive</u> to download samples of our research. New Constructs is a <u>BBB accredited</u> business and a member of the <u>Investorside Research Association</u>.



DISCLOSURES

New Constructs®, LLC (together with any subsidiaries and/or affiliates, "New Constructs") is an independent organization with no management ties to the companies it covers. None of the members of New Constructs' management team or the management team of any New Constructs' affiliate holds a seat on the Board of Directors of any of the companies New Constructs covers. New Constructs does not perform any investment or merchant banking functions and does not operate a trading desk.

New Constructs' Stock Ownership Policy prevents any of its employees or managers from engaging in Insider Trading and restricts any trading whereby an employee may exploit inside information regarding our stock research. In addition, employees and managers of the company are bound by a code of ethics that restricts them from purchasing or selling a security that they know or should have known was under consideration for inclusion in a New Constructs report nor may they purchase or sell a security for the first 15 days after New Constructs issues a report on that security.

New Constructs is affiliated with Novo Capital Management, LLC, the general partner of a hedge fund. At any particular time, New Constructs' research recommendations may not coincide with the hedge fund's holdings. However, in no event will the hedge fund receive any research information or recommendations in advance of the information that New Constructs provides to its other clients.

DISCLAIMERS

The information and opinions presented in this report are provided to you for information purposes only and are not to be used or considered as an offer or solicitation of an offer to buy or sell securities or other financial instruments. New Constructs has not taken any steps to ensure that the securities referred to in this report are suitable for any particular investor and nothing in this report constitutes investment, legal, accounting or tax advice. This report includes general information that does not take into account your individual circumstance, financial situation or needs, nor does it represent a personal recommendation to you. The investments or services contained or referred to in this report may not be suitable for you and it is recommended that you consult an independent investment advisor if you are in doubt about any such investments or investment services.

Information and opinions presented in this report have been obtained or derived from sources believed by New Constructs to be reliable, but New Constructs makes no representation as to their accuracy, authority, usefulness, reliability, timeliness or completeness. New Constructs accepts no liability for loss arising from the use of the information presented in this report, and New Constructs makes no warranty as to results that may be obtained from the information presented in this report. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information and opinions contained in this report reflect a judgment at its original date of publication by New Constructs and are subject to change without notice. New Constructs may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and New Constructs is under no obligation to insure that such other reports are brought to the attention of any recipient of this report.

New Constructs' reports are intended for distribution to its professional and institutional investor customers. Recipients who are not professionals or institutional investor customers of New Constructs should seek the advice of their independent financial advisor prior to making any investment decision or for any necessary explanation of its contents.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would be subject New Constructs to any registration or licensing requirement within such jurisdiction.

This report may provide the addresses of websites. Except to the extent to which the report refers to New Constructs own website material, New Constructs has not reviewed the linked site and takes no responsibility for the content therein. Such address or hyperlink (including addresses or hyperlinks to New Constructs own website material) is provided solely for your convenience and the information and content of the linked site do not in any way form part of this report. Accessing such websites or following such hyperlink through this report shall be at your own risk.

All material in this report is the property of, and under copyright, of New Constructs. None of the contents, nor any copy of it, may be altered in any way, copied, or distributed or transmitted to any other party without the prior express written consent of New Constructs. All trademarks, service marks and logos used in this report are trademarks or service marks or registered trademarks or service marks of New Constructs.

Copyright New Constructs, LLC 2003 through the present date. All rights reserved.